US Edition
FDA Approves First Non-Opioid Painkiller in Over Two Decades
- The U.S. Food and Drug Administration approved Vertex Pharmaceuticals' Journavx for short-term pain, marking the first new painkiller in over 20 years, according to federal officials.
- Journavx works by blocking proteins that trigger pain signals, differing from opioids, which bind to brain receptors, according to Dr. David Altshuler of Vertex.
- Biotechnology analyst Brian Abrahams expressed concerns that disappointing study results could jeopardize the financial value of Vertex's pain management pipeline.
268 Articles
268 Articles
Following its recent FDA approval, people are expected to take two pills of Journavx daily, which represents a cost of $31
It's the first non-opiate drug on the market in 25 years. The drug works through a new mechanism of action, and could be a huge step forward in addressing the opioid crisis. The bad news is that it's much more expensive than opiates.
Vertex Pharmaceuticals obtained U.S. approval for the first new type of painkiller in more than two decades, paving the way for a safer alternative to addictive opioids that have been associated with hundreds of thousands of deaths.The Vertex pill, called Journavx, obtained authorization from the Food and Drug Administration to treat acute pain from moderate to severe, according to a Thursday statement. The wholesale purchase cost for the drug t…
FDA Approves First New Non-Opioid Pain Reliever in Decades
The FDA has given the green light to a new non-opioid medication called Journavx, intended for managing moderate-to-severe acute pain in adults. This is the first approval of its kind in over two decades, marking a significant development in pain management. Produced by Vertex Pharmaceuticals, Journavx works by blocking pain signals in the peripheral nervous
FDA approves non-opioid painkiller, first new class in decades
The FDA approved the first new class of non-opioid painkillers in more than two decades, the agency said Thursday. Suzetrigine, branded as Journavx, works to block receptors before they reach the brain in patients with surgical or injury pain.
Coverage Details
Bias Distribution
- 70% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
